Leerink Swann reissued their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note released on Wednesday morning. They currently have a $169.00 target price on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on ALXN. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 14th. They issued an outperform rating and a $161.00 target price on the stock. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a neutral rating to an overweight rating and boosted their target price for the company from $163.00 to $175.00 in a research note on Tuesday, September 5th. Deutsche Bank restated a buy rating and issued a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. SunTrust Banks restated a buy rating and issued a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, BMO Capital Markets restated an outperform rating and issued a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of Buy and an average target price of $154.49.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up $0.52 during trading hours on Wednesday, hitting $109.42. 1,935,700 shares of the stock traded hands, compared to its average volume of 2,286,650. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The firm has a market cap of $24,329.31, a P/E ratio of 22.27, a PEG ratio of 1.18 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the previous year, the company earned $1.23 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. equities research analysts predict that Alexion Pharmaceuticals will post 4.82 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in ALXN. Russell Investments Group Ltd. lifted its position in Alexion Pharmaceuticals by 22.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 35,588 shares of the biopharmaceutical company’s stock valued at $4,331,000 after purchasing an additional 6,438 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at about $160,000. NGAM Advisors L.P. increased its stake in shares of Alexion Pharmaceuticals by 24.5% in the 2nd quarter. NGAM Advisors L.P. now owns 16,953 shares of the biopharmaceutical company’s stock valued at $2,063,000 after acquiring an additional 3,335 shares during the last quarter. Rothschild Asset Management Inc. bought a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at about $647,000. Finally, Daiwa Securities Group Inc. increased its stake in shares of Alexion Pharmaceuticals by 3.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 6,300 shares of the biopharmaceutical company’s stock valued at $767,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 94.16% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/07/alexion-pharmaceuticals-alxn-given-buy-rating-at-leerink-swann.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.